RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

A small business loan is a source of capital that can help you stock your shelves, buy new equipment or expand your footprint. Business owners can access financing through traditional banks ...

According to the Complaint, the Company made false and misleading statements to the market. Regeneron paid credit card fees to distributors on the condition that those distributors did not charge ...

Cramer discussed how Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) keeps getting undermined despite the company’s rich pipeline and its strength in drug development. “How about Regeneron?

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

We list the best small business apps, to make it simple and easy to manage your business, whether you're working from home, the office, or on the go. Small business owners know the need to remain ...